Avatropag 20 mg contains Avatrombopag Maleate, an orally active thrombopoietin receptor agonist (TPO-RA) used to manage thrombocytopenia (low platelet count) in specific clinical conditions. It is designed to stimulate platelet production by activating the thrombopoietin receptor, thereby reducing the risk of bleeding and minimizing the need for platelet transfusions in eligible patients.

Avatropag works by binding to and activating the thrombopoietin (TPO) receptor on megakaryocyte progenitor cells in the bone marrow. This stimulation promotes the proliferation and differentiation of megakaryocytes, leading to an increased production of platelets. Unlike platelet transfusions, Avatropag helps the body produce its own platelets, offering a convenient and effective oral treatment option.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Avatropag 20 mg is indicated for:

• Treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a medical or dental procedure.

• Treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to previous treatments.

Therapeutic Class

• Thrombopoietin Receptor Agonist

Pharmacology

Avatrombopag selectively activates the TPO receptor without competing with endogenous thrombopoietin. This targeted mechanism increases platelet counts in a dose-dependent manner. The drug is orally absorbed and demonstrates predictable pharmacokinetics, allowing for consistent platelet response when taken as prescribed. Platelet counts typically rise within several days of initiation.

Dosage and Administration

• Dosage is individualized based on indication, baseline platelet count, and patient response.

• Avatropag is administered orally and should be taken with food to enhance absorption.

• Treatment duration and dose adjustments should be guided by platelet monitoring and physician recommendation.

Key Benefits

• Oral administration for improved patient convenience.

• Reduces or eliminates the need for platelet transfusions.

• Predictable and sustained platelet response.

• Suitable for short-term use before procedures and long-term management in chronic conditions.

Precautions and Warnings

• Platelet counts should be monitored regularly to avoid excessive elevation, which may increase thrombotic risk.

• Use with caution in patients with known risk factors for thromboembolism.

• Not indicated for the treatment of myelodysplastic syndromes or thrombocytopenia due to causes other than approved indications.

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Adverse Effects

Commonly reported adverse effects may include headache, fatigue, nausea, abdominal discomfort, and peripheral edema. Most side effects are mild to moderate in severity. Patients should report any unusual symptoms to their healthcare provider.

Storage

Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children.

Avatropag 20 mg offers a reliable and effective oral solution for the management of thrombocytopenia, supporting safer procedural outcomes and improved quality of life for patients with chronic platelet disorders.